269 related articles for article (PubMed ID: 31311652)
1. Avoiding Overtreatment of Ductal Carcinoma in situ.
van der Borden CL; Stoffers S; Lips EH; Wesseling J
Trends Cancer; 2019 Jul; 5(7):391-393. PubMed ID: 31311652
[TBL] [Abstract][Full Text] [Related]
2. Preventing Overdiagnosis and Overtreatment: Just the Next Step in the Evolution of Breast Cancer Care.
Mukhtar RA; Wong JM; Esserman LJ
J Natl Compr Canc Netw; 2015 Jun; 13(6):737-43. PubMed ID: 26085389
[TBL] [Abstract][Full Text] [Related]
3. Finding the balance between over- and under-treatment of ductal carcinoma in situ (DCIS).
Groen EJ; Elshof LE; Visser LL; Rutgers EJT; Winter-Warnars HAO; Lips EH; Wesseling J
Breast; 2017 Feb; 31():274-283. PubMed ID: 27671693
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis of ductal carcinoma in situ in an era of de-escalation of therapy.
Schnitt SJ
Mod Pathol; 2021 Jan; 34(Suppl 1):1-7. PubMed ID: 32908254
[TBL] [Abstract][Full Text] [Related]
5. Ductal carcinoma in situ of the breast: diagnosis and management.
Friedrich M; Felberbaum R; Krämer S; Axt-Fliedner R; Diedrich K
Onkologie; 2003 Dec; 26(6):588-95. PubMed ID: 14709936
[TBL] [Abstract][Full Text] [Related]
6. The distribution of ductal carcinoma in situ (DCIS) grade in 4232 women and its impact on overdiagnosis in breast cancer screening.
van Luijt PA; Heijnsdijk EA; Fracheboud J; Overbeek LI; Broeders MJ; Wesseling J; den Heeten GJ; de Koning HJ
Breast Cancer Res; 2016 May; 18(1):47. PubMed ID: 27160733
[TBL] [Abstract][Full Text] [Related]
7. Can dedicated breast PET help to reduce overdiagnosis and overtreatment by differentiating between indolent and potentially aggressive ductal carcinoma in situ?
Graña-López L; Herranz M; Domínguez-Prado I; Argibay S; Villares Á; Vázquez-Caruncho M
Eur Radiol; 2020 Jan; 30(1):514-522. PubMed ID: 31375867
[TBL] [Abstract][Full Text] [Related]
8. Ductal carcinoma in situ (DCIS) of the breast: evolving perspectives.
Sakorafas GH; Tsiotou AG
Cancer Treat Rev; 2000 Apr; 26(2):103-25. PubMed ID: 10772968
[TBL] [Abstract][Full Text] [Related]
9. The method of detection of ductal carcinoma in situ has no therapeutic implications: results of a population-based cohort study.
Elshof LE; Schaapveld M; Rutgers EJ; Schmidt MK; de Munck L; van Leeuwen FE; Wesseling J
Breast Cancer Res; 2017 Mar; 19(1):26. PubMed ID: 28274272
[TBL] [Abstract][Full Text] [Related]
10. Ductal carcinoma in situ: to treat or not to treat, that is the question.
van Seijen M; Lips EH; Thompson AM; Nik-Zainal S; Futreal A; Hwang ES; Verschuur E; Lane J; Jonkers J; Rea DW; Wesseling J;
Br J Cancer; 2019 Aug; 121(4):285-292. PubMed ID: 31285590
[TBL] [Abstract][Full Text] [Related]
11. Modeling the natural history of ductal carcinoma in situ based on population data.
Chootipongchaivat S; van Ravesteyn NT; Li X; Huang H; Weedon-Fekjær H; Ryser MD; Weaver DL; Burnside ES; Heckman-Stoddard BM; de Koning HJ; Lee SJ
Breast Cancer Res; 2020 May; 22(1):53. PubMed ID: 32460821
[TBL] [Abstract][Full Text] [Related]
12. Overtreatment in surgery - does it concern also the patients with ductal breast carcinoma in situ.
Nowikiewicz T; Zegarski W; Głowacka-Mrotek I
Pol Przegl Chir; 2018 Feb; 90(1):47-51. PubMed ID: 29513252
[TBL] [Abstract][Full Text] [Related]
13. Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology.
Gradishar WJ; Anderson BO; Balassanian R; Blair SL; Burstein HJ; Cyr A; Elias AD; Farrar WB; Forero A; Giordano SH; Goetz MP; Goldstein LJ; Isakoff SJ; Lyons J; Marcom PK; Mayer IA; McCormick B; Moran MS; O'Regan RM; Patel SA; Pierce LJ; Reed EC; Salerno KE; Schwartzberg LS; Sitapati A; Smith KL; Smith ML; Soliman H; Somlo G; Telli ML; Ward JH; Kumar R; Shead DA
J Natl Compr Canc Netw; 2018 Mar; 16(3):310-320. PubMed ID: 29523670
[TBL] [Abstract][Full Text] [Related]
14. Valuing preferences for treating screen detected ductal carcinoma in situ.
Bromley HL; Mann GB; Petrie D; Nickson C; Rea D; Roberts TE
Eur J Cancer; 2019 Dec; 123():130-137. PubMed ID: 31689678
[TBL] [Abstract][Full Text] [Related]
15. Some clarity in the management of DCIS in breast cancer screening.
Wald NJ
J Med Screen; 2011; 18(3):112. PubMed ID: 22045817
[No Abstract] [Full Text] [Related]
16. Current approach and future perspective for ductal carcinoma in situ of the breast.
Kanbayashi C; Iwata H
Jpn J Clin Oncol; 2017 Aug; 47(8):671-677. PubMed ID: 28486668
[TBL] [Abstract][Full Text] [Related]
17. The ductal carcinoma in situ (DCIS) dilemma.
Gur D
Acad Radiol; 2010 Feb; 17(2):133-4. PubMed ID: 20123347
[No Abstract] [Full Text] [Related]
18. Addressing overtreatment of screen detected DCIS; the LORIS trial.
Francis A; Thomas J; Fallowfield L; Wallis M; Bartlett JM; Brookes C; Roberts T; Pirrie S; Gaunt C; Young J; Billingham L; Dodwell D; Hanby A; Pinder SE; Evans A; Reed M; Jenkins V; Matthews L; Wilcox M; Fairbrother P; Bowden S; Rea D
Eur J Cancer; 2015 Nov; 51(16):2296-303. PubMed ID: 26296293
[TBL] [Abstract][Full Text] [Related]
19. Are There Alternative Strategies for the Local Management of Ductal Carcinoma in Situ?
Rosso KJ; Weiss A; Thompson AM
Surg Oncol Clin N Am; 2018 Jan; 27(1):69-80. PubMed ID: 29132566
[TBL] [Abstract][Full Text] [Related]
20. The long-term psychosocial consequences of screen-detected ductal carcinoma in situ and invasive breast cancer.
Gram EG; Manso TFR; Heleno B; Siersma V; Á Rogvi J; Brodersen JB
Breast; 2023 Aug; 70():41-48. PubMed ID: 37307773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
